This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00886/identifier/pubchem-compound/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00886/identifier/kegg-drug/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00886/identifier/pubchem-substance/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00886/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB00886/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB00886/identifier/wikipedia/

Statements

Subject Item
n2:DB00886
rdf:type
n3:Drug
n3:description
Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling. This drug from BMS was not approved by the FDA due to angioedema safety concerns.
n3:generalReferences
# Rabkin SW, Klassen SS: Omapatrilat enhances adrenomedullin's reduction of cardiomyocyte cell death. Eur J Pharmacol. 2007 May 21;562(3):174-82. Epub 2007 Feb 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17343842
n3:group
investigational
n3:indication
For the treatment of hypertension.
owl:sameAs
n6:DB00886
dcterms:title
Omapatrilat
adms:identifier
n9:Omapatrilat n10:112074 n11:126046 n12:702772 n13:DB00886 n14:D01970
n3:mechanismOfAction
Omapatrilat binds to both angiotensin converting enzyme and neutral endopeptidase. This results in a decrease renin-angiotensin-aldosterone production and increase natriuretic peptidase circulation.
n3:toxicity
Side effects include hyperkalemia, cough, hypotension, increased SrCr, and dizziness. Dizziness, diarrhea, vision disturbance, hypotension and angioedema
n3:IUPAC-Name
n4:271B5829-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B582F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B582E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B582B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B582C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B582D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5827-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5825-363D-11E5-9242-09173F13E4C5 n4:271B5828-363D-11E5-9242-09173F13E4C5 n4:271B583F-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5826-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5835-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5836-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5830-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5831-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5833-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5832-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5834-363D-11E5-9242-09173F13E4C5
n3:absorption
The absolute oral bioavailability of omapatrilat is 20% to 30% and the absorption is not affected by food intake.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
167305-00-2
n3:Bioavailability
n4:271B583B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B583D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B583E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B583A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5839-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B583C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B582A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5837-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5838-363D-11E5-9242-09173F13E4C5